Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease.

ABSTRACT:

Purpose

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an entity closely linked to obesity and/or insulin resistance, projected to affect about half of the global adult population by 2040. New therapeutic strategies that are both effective and affordable are needed to address this impending public health crisis.

Methods

A narrative review was conducted to identify studies supporting the use of levothyroxine and thyroid hormone analogs in treating MASLD and metabolic dysfunction-associated steatohepatitis (MASH).

Results

Clinical studies have identified clear pathophysiological links between low (or low-normal) thyroid function and increased risk of hepatic steatosis. Of the two main thyroid hormone receptor (THR) isoforms, THRα and THRβ, the latte

SUBMITTER: Duntas LH 

PROVIDER: S-EPMC12708833 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature